In Trading, Results Matter.
Our Top 10 exits in last 5 trading days.

GLOBAL BLOOD THERAPEUTICS, INC.. Trade Record

NASDAQ:GBT GLOBAL BLOOD THERAPEUTICS, INC. stock gains 23.32% Exit Jan 31, 2018 a Trade Record by priceseries

Trade Chart
Trade Chart GBT Jan 9, 2018, priceSeries
About GLOBAL BLOOD THERAPEUTICS, INC.

Global Blood Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics to treat grievous blood-based disorders. Its lead product candidate is GBT440, a hemoglobin modifier that binds to hemoglobin molecules, which is in Phase 3 clinical trial for the treatment of sickle cell disease (SCD) in adult and adolescent patients, as well as evaluates the safety and pharmacokinetics of single and multiple doses of GBT440 on adolescent patients with SCD. The company is also involved in conducting Phase 2 clinical trials of GBT440 for the treatment of idiopathic pulmonary fibrosis, which is a hypoxemic pulmonary disorder; and other pre-clinical research and development activities. Global Blood Therapeutics Inc. was founded in 2011 and is headquartered in South San Francisco, California.

Trade Information
Trade Type
LONG
ReliabilityScore™
97.06
Entry Date
Jan 9, 2018
Entry Price
47.15
Sell Date
Jan 31, 2018
Sell Price
58.14
Net Gain
23.32%
Hold Time
15 Trading Days